10-Q: Microbot Medical Boosts Liquidity Amid R&D Push

Microbot Medical reports significant capital raises and increased liquidity to fund ongoing research and development for its robotic surgical systems, despite widening net losses.

Summary

• Net loss for the three months ended June 30, 2025, was $3.5 million, an increase from $2.465 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, was $6.101 million, up from $4.836 million in the first half of 2024.
• Cash and cash equivalents increased to $4.082 million as of June 30, 2025, from $3.114 million at December 31, 2024.
• Marketable securities significantly rose to $28.592 million as of June 30, 2025, compared to $2.356 million at December 31, 2024.
• Total current assets reached $32.891 million, a substantial increase from $5.819 million at year-end 2024.
• Net working capital improved to approximately $30.2 million as of June 30, 2025, from $3.4 million at December 31, 2024.
• Research and development expenses, net, increased to $2.111 million for Q2 2025 and $3.570 million for H1 2025, compared to $1.417 million and $2.586 million respectively in 2024.
• General and administrative expenses increased to $1.612 million for Q2 2025 and $3.174 million for H1 2025, compared to $1.094 million and $2.309 million respectively in 2024.
• Financing income, net, grew to $223 thousand for Q2 2025 and $327 thousand for H1 2025, up from $46 thousand and $59 thousand respectively in 2024.
• The company raised $32.558 million in net cash from financing activities during the first six months of 2025.
• Outstanding common stock as of August 10, 2025, was 45,545,939 shares.
• A judgment of approximately $316 thousand was received from the Mona litigation.
• A new grant of approximately $630,000 was approved by the Israeli Innovation Authority in July 2025 for the LIBERTY Endovascular Robotic Surgical System manufacturing process development.

Sentiment

Score: 6

Explanation: While the company continues to incur significant losses and expenses, it has substantially improved its liquidity through successful capital raises and grants, which is crucial for a pre-commercial, clinical-stage company. Progress on product development and regulatory submissions (FDA 510(k), ISO certification) is positive, but commercialization is still in the future, and geopolitical risks remain. The increased losses are expected for a company in this stage.

Positives

• Significant increase in cash and marketable securities, resulting in approximately $32.674 million in liquidity (excluding restricted cash) as of June 30, 2025.
• Successful capital raises totaling over $32.5 million in H1 2025, and an additional $13.275 million in gross proceeds from warrant exercises in July-August 2025, providing a substantial financial runway.
• Management believes available funds are sufficient to fund operations for more than twelve months from the financial statement issuance date.
• Successful resolution of the Mona litigation, resulting in approximately $316 thousand in other income.
• Approval of a new grant of approximately $630,000 from the Israeli Innovation Authority for LIBERTY Endovascular Robotic Surgical System manufacturing process development.
• Received ISO 13485:2016 certification for its quality management system, supporting future CE Mark approval and streamlining transition into revised FDA regulation.
• Successful preclinical studies for LIBERTY Endovascular Robotic Surgical System, including a 100% success rate in reaching targets in a two-day study and 100% usability/technical success in a pivotal preclinical study.
• Submission of 510(k) premarket notification to the FDA for the LIBERTY Endovascular Robotic System following successful completion of a multi-center human trial.
• Increased authorized common stock to 120,000,000 shares, providing flexibility for future capital raises.
• Increased financing income due to investments of raised capital.

Negatives

• Continued net losses, increasing to $3.5 million for Q2 2025 and $6.101 million for H1 2025.
• Increased research and development expenses, primarily due to outsourcing manufacturing and higher payroll.
• Increased general and administrative expenses due to higher payroll and recruiting fees.
• No revenues generated from operations to date, indicating continued reliance on external funding.
• Potential for significant dilution to shareholders from future equity issuances.
• Incurrence of additional debt could result in restrictive debt service obligations and covenants.

Risks

• The ability to raise additional capital is dependent on market demand for the company's stock and favorable terms, with no assurance of success.
• Ongoing Israel-Hamas War and related military operations in the region could adversely affect anticipated milestones and Israel-based activities, including subcontractor operations and international flights.
• The company does not have specific contingency plans in the event of escalation or change in the Israel-Hamas War.
• Issuance of preferred stock could adversely affect the voting power of common stockholders and reduce dividend/liquidation payments, potentially delaying or deterring a change in control.
• Anti-takeover provisions, such as a staggered board and strict nomination requirements, may deter beneficial takeover attempts.
• Foreign exchange rate fluctuations may adversely impact future revenues or expenses.
• Maintaining significant amounts of cash and cash equivalents at financial institutions in excess of federally insured limits.
• Uncertainty in meeting projected milestones for FDA marketing clearance (Q3 2025) and CE Mark approval (H2 2026) for the LIBERTY system.
• Obligation to pay royalties on future sales of products developed with Israeli Innovation Authority (IIA) and Ministry of Economy grants.
• Restriction from transferring technologies developed with IIA grants outside of Israel without prior approval.
• An employment-related matter with a former employee, though currently assessed as without merit, could lead to litigation with an uncertain outcome.

Future Outlook

The company anticipates FDA marketing clearance for the LIBERTY Endovascular Robotic System during the third quarter of 2025, with U.S. commercialization activities expected to commence after clearance. CE Mark approval is anticipated in the second half of 2026. The company expects to continue incurring additional losses for the foreseeable future due to ongoing research and development and pre-commercialization activities. Management believes current available funds, combined with recent capital raises, are sufficient to fund operations for more than twelve months from the financial statement issuance date. The company expects to raise additional funds through future issuances of debt and/or equity securities, including upon the cash exercise of outstanding investment options, and additional grants from the Israeli Innovation Authority and other government institutions.

Management Comments

• "Management has concluded that the available funds as of the balance sheet date, combined with the capital raises completed as described in Note 4, are sufficient to fund the Company’s operations for more than twelve months from the issuance date of these financial statements."
• "The Company expects to raise additional funds through future issuances of either debt and/or equity securities, including upon the cash exercise of outstanding investment options, and additional grants from the Israeli Innovation Authority and other government institutions."
• "As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations [due to Israel-Hamas War], but the Company continues to monitor the situation, as any collapse of a cease-fire with any nation or group hostile to Israel from time to time, or any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support its clinical and regulatory activities."
• "The Company does not have any specific contingency plans in the event of any such escalation or change [in Israel-Hamas War]."
• "We anticipate FDA marketing clearance during the third quarter of 2025, with U.S. commercialization activities expected to commence after the clearance. However, we can give no assurance that we will meet this projected milestone, if ever."
• "We anticipate CE Mark approval in the second half of 2026. However, we can give no assurance that we will meet this or any other projected milestones, if ever."
• "As of the filing date of this Quarterly Report on Form 10-Q, management believes we have sufficient funds for our operations for in excess of one year."

Industry Context

The company operates in the rapidly evolving medical device industry, specifically focusing on robotic endoluminal surgery and minimally invasive procedures. Its LIBERTY system aims to redefine surgical robotics by offering a compact, mobile, and fully disposable robot, potentially expanding telerobotic interventions. This aligns with broader industry trends towards less invasive procedures, remote healthcare, and automation in surgery. The focus on reducing radiation exposure and physical strain for physicians addresses key ergonomic and safety concerns in interventional radiology.

Comparison to Industry Standards

• The LIBERTY Endovascular Robotic Surgical System is described as the 'first ever fully disposable robot for various endovascular interventional procedures,' which, if validated, would represent a significant innovation in the robotic surgery market.
• The system aims to eliminate the need for extensive capital equipment and dedicated Cath-lab rooms, suggesting a competitive advantage in terms of cost and operational flexibility compared to existing larger robotic systems.
• The company's research collaboration with Corewell Health demonstrated the feasibility of remote operation, aligning with the growing trend of telemedicine and remote healthcare delivery.
• Preclinical studies for LIBERTY show high success rates (95% to 100%) in reaching vascular targets, indicating strong technical performance for a device in its development stage.
• Receiving ISO 13485:2016 certification ensures compliance with international quality management system requirements, aligning with global medical device standards like EU MDR 2017/745, which is crucial for market access.

Corporate Governance

Legal Proceedings

• Resolved a lawsuit (Empery Asset Master Ltd. et al. vs. Microbot Medical Inc.) related to the 2017 financing, settling on January 26, 2024, for $2.154 million (cash and restricted common stock), with the cash portion covered by insurance.
• An appellate court ruled in favor of the Company in March 2025 regarding a 2019 action against Alliance Investment Management, Ltd. and Joseph Mona, resulting in a judgment of approximately $316 thousand received by the Company, with a subsequent petition to the U.S. Supreme Court denied.
• Received a demand letter on June 17, 2025, from legal counsel representing a former employee regarding an employment-related matter; the company believes the claims are without merit, and no legal proceedings have been initiated as of the balance sheet date.

Stakeholder Impact

• Shareholders face potential dilution from ongoing and future equity issuances but benefit from significantly increased liquidity and a longer operational runway, which de-risks the company's development phase.
• Employees benefit from increased payroll, bonuses, and share-based compensation, indicating continued investment in human capital.
• Future customers (physicians and patients) stand to benefit from the potential commercialization of the LIBERTY system, which aims to improve surgical outcomes, reduce radiation exposure, and alleviate physical strain.
• Suppliers and subcontractors, particularly those in Israel, may experience operational disruptions due to the ongoing Israel-Hamas War, potentially impacting the company's supply chain.
• Creditors may see increased debt levels if the company opts for debt financing in the future, which could introduce new covenants and obligations.

Next Steps

• Anticipate FDA marketing clearance for the LIBERTY Endovascular Robotic System during Q3 2025.
• Commence U.S. commercialization activities for LIBERTY after FDA clearance.
• Anticipate CE Mark approval for LIBERTY in H2 2026.
• Continue to raise capital through future public and private issuances of debt and/or equity securities.
• Continue to seek additional grants from the Israeli Innovation Authority and other government institutions.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial position.
• Monitor the Israel-Hamas War situation for potential adverse effects on operations.
• Address the employment-related matter, if litigation is commenced.

Key Dates

Recommendation

The company is in a critical pre-commercial, clinical-stage phase with no revenues, incurring substantial and increasing losses. However, it has significantly bolstered its cash position through recent capital raises, providing a longer runway for operations and continued development of its robotic surgical systems. Positive progress on regulatory submissions (FDA 510(k) and ISO certification) and preclinical study results are encouraging. The geopolitical risks in Israel are a concern, but the company states no material adverse effects to date. The stock is speculative given its stage, but the improved liquidity and development milestones warrant a 'Hold' for investors willing to tolerate high risk and monitor future commercialization progress.

Keywords

Robotic surgery, Endovascular, Medical device, Minimally invasive surgery, LIBERTY Endovascular Robotic Surgical System, NovaCross, SEC filing, 10-Q, Microbot Medical, MBOT, Clinical stage, FDA clearance, CE Mark, Israel Innovation Authority, Capital raise, Liquidity, Research and development